Efgartigimod is an FcRn inhibitor that treats autoimmune diseases by reducing circulating IgG antibody levels, thereby reducing the levels of pathogenic IgG autoantibodies, as in generalized myasthenia gravis and IgG4-related disease (3, 18). The gene discussed is FCGRT; the disease is immunoglobulin G4-related sclerosing disease.